After pulling the plug on an $86 million float in biotech's halcyon 2013, Vital Therapies has made its way to Wall Street with a scaled-down $54 million offering, cash it will use to advance its drug-device combo for liver failure.
Galapagos and partner GlaxoSmithKline say their anti-inflammation candidate hit its mark in a mid-stage trial on psoriasis, a stroke of good news for a drug beset by developmental slipups.
The industry analysts at Thomson Reuters put their heads together to tap the biggest new blockbusters in the making this year and surprised no one by capping the list with Gilead's Sovaldi.
Baxter charted another late-stage success in its growing hemophilia franchise, posting positive top-line results for an orphan bleeding disorder treatment.
Boehringer Ingelheim wants to be considered part of the major league in global drug R&D. And it's been spending some blockbuster cash on a bid to win a big slate of new drug approvals that could eclipse even the biggest rivals.
Uniondale, NY's Angion Biomedica is eyeing $36 million to bankroll its pipeline of treatments for organ injury, hoping to buck an alarming trend for biotech stocks and trade on the Nasdaq under "ANGN."
Investigators for Intercept Pharmaceuticals spelled out the impact of its lead therapy on rare cases of a liver disease called primary biliary cirrhosis (PBC), fleshing out the results of a late-stage study that it will use to seek U.S. and European approvals later in the year.
While AbbVie is widely expected to be the second entrant to the soon-to-explode market for hepatitis C cocktail drugs after standard-bearer Gilead Sciences, promising data from latecomer Merck have analysts relegating the Illinois company to third place despite some excellent late-stage results.
Three days after Bristol-Myers Squibb filed for FDA approval of the NS5A drug daclatasvir combined with asunaprevir, an NS3 protease inhibitor, the biotech company has turned over some of the Phase III cards it will be playing for an approval in markets around the world.
Biogen Idec's long-acting hemophilia A drug performed well in a late-stage study on children, the biotech said, giving it another Phase III victory as it races with rivals Bayer and Novo Nordisk to launch a more convenient treatment for the bleeding disorder.